Medicare announces new payment rates for COVID-19 monoclonal antibody infusions
Effective immediately, Medicare will pay $750 to administer monoclonal antibodies to COVID-19 patients in their residence or temporary lodging and increase payment to administer them in most other care settings to $450 from $310 to better align payment with provider costs, the Centers for Medicare & Medicaid Services announced yesterday. CMS is updating its COVID-19 toolkits and coding resources to reflect the new payment rates.
Related News Articles
Headline
The Medicare Part A deductible for inpatient hospital services will increase by $60 in calendar year 2026 to $1,736, the Centers for Medicare & Medicaid…
Headline
Aetna’s new “level of severity inpatient payment” policy is now set to take effect Jan. 1, 2026, the company recently announced, along with providing…
Headline
The 43-day government shutdown ended last night when President Trump signed a funding bill into law, hours after the House passed the measure by a 222-209 vote…
Headline
The Centers for Medicare & Medicaid Services is launching a new initiative for state Medicaid programs to purchase prescription drugs at prices aligned…
Headline
The AHA commented Nov. 3 on the Centers for Medicare & Medicaid Services’ calendar year 2026 final rule for the physician fee schedule. The rule, released…
Headline
The Centers for Medicare & Medicaid Services Oct. 31 released its calendar year 2026 final rule for the physician fee schedule. As required by law,…